SHP2

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after several other drugmakers have suffered setbacks. The New York drugmaker ended the Phase 1 study of the drug, PF-07284892, “due to strategic reasons, not major safety concerns, futility, or requests from any regulatory authorities,” according to the trial registry update. The experimental medicine is still listed in Pfizer’s pipeline on its website. A spokesperson for the company didn’t provide comment as of publication time. Pfizer acquired the drug as part of its 2019 buyout of Array BioPharma. The $11.4 billion deal came with a portfolio of approved and in-development cancer treatments. It’s not the first company to walk away from SHP2. Earlier this year, Roche ended a pact with Relay Therapeutics, and Bristol Myers Squibb also left a collaboration. AbbVie and Sanofi have ended SHP2 partnership deals as well. Pfizer once hoped for better for its drug, however. In February, Chief Oncology Officer Chris Boshoff described the drug as “differentiated” and “best-in-class.” “The two or three that’s in the clinic has been challenging in terms of side effects, and we don’t see that,” Boshoff said during the company’s oncology innovation day, according to a transcript from AlphaSense. Pfizer was testing PF-07284892 alone and in combination with other drugs, including two of the products that came from the Array deal. The move is one of several cutbacks to Array’s work, including the shutdown of a site in Colorado earlier this year. It’s been a volatile month for Pfizer, which is facing an activist investor and last week stopped developing an investigational RSV treatment, then secured an FDA approval for a hemophilia treatment .

SEOUL, South Korea I October 08, 2024 I Ubix Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of innovative oncology therapeutics using Targeted Protein Degradation (TPD) technology, announced today its acceptance as a member of the Johnson & Johnson Innovation – JLABS (JLABS) Korea community. JLABS is one of the largest global networks of health incubators pioneering the next wave of healthcare solutions with early-stage innovators. Powered by Johnson & Johnson, JLABS empowers its member companies working across the spectrum of healthcare with the experience, mentorship, partnerships and venture connections to accelerate their science. Ubix Therapeutics is currently conducting a phase 1 clinical trial for UBX-303-1, an oral small molecule degrader targeting B cell malignancies. In July, the company inked a license agreement granting Yuhan Corporation the rights to develop and commercialize AR degrader UBX-103, a prostate cancer drug candidate. “Our acceptance into JLABS is a tremendous opportunity for us to accelerate our R&D efforts.” said BK Seo, CEO of Ubix Therapeutics. “We plan to leverage the membership to further advance our pipeline, including UBX-106, a SHP2 degrader program set to enter IND-enabling studies, and to strengthen our efforts in building global partnerships.” About Ubix Therapeutics, INC. Ubix Therapeutics is a biotechnology company dedicated to discovery and development of TPD therapeutics. Ubix’ proprietary TPD platform technology, Degraducer®, leverages the body’s own natural protein degradation machinery to eliminate diseased proteins, thereby leading to near-complete inactivation of disease-causing pathways. Ubix’ wholly owned TPD pipeline includes its clinical program UBX-303-1, a BTK degrader for treatment of relapsed or refractory B cell malignancies, UBX-106, a SHP2 degrader set to enter IND-enabling studies for MAPK signaling dependent cancers, and multiple other preclinical and research stage degrader assets in targeted and immuno-oncology. For additional information, please visit http://en.ubixtrx.com SOURCE: Ubix Therapeutics

On September 27, 2024, Jacobio Pharma (stock code: 1167.HK) attracted a lot of attention in the industry when it officially announced a major cooperation development - the successful acquisition of Shanghai Ellis Pharmaceutical Technology Co., LTD. (stock code: 688578.SH) received up to 172 million yuan in cooperation funds. This payment not only marks the depth and stability of the cooperation between the two parties, but also demonstrates the excellent strength and extensive influence of Gax in the field of innovative drug research and development. The composition of this cooperation is quite remarkable, including a down payment of 150 million yuan, which is a direct reflection of Ellis' high recognition and value of Gax's research and development results. In addition, there is also 22.79 million RMB as research and development cost compensation and other related payments, which will strongly support Gax's continued investment and innovation exploration in subsequent research and development projects. Looking back at the history of cooperation between the two parties, it all began with the signing of a landmark cooperation agreement on August 30, 2024.This initiative not only shows CAx's trust and respect for its partners, but also reflects its firm determination to promote the development of China and even the global medical and health cause. KRAS G12C inhibitor Golelexel, as a star drug in the field of tumor therapy in recent years, has won widespread praise worldwide for its unique mechanism of action and remarkable efficacy. The SHP2 inhibitor JAB-3312 is another effort of GaX in the field of precision medicine, and its precision strike ability for specific targets has brought new hope to many patients with refractory diseases. The introduction of these two drugs will undoubtedly inject new vitality into Ellis' product line and further consolidate its leading position in the pharmaceutical market. It is worth noting that this cooperation not only reflects the depth of cooperation between the two sides in the field of drug research and development, but also indicates that China's pharmaceutical industry is gradually moving toward a new stage of internationalization and high-end. As the global pharmaceutical market continues to integrate and competition intensifies, Chinese pharmaceutical companies are enhancing their core competitiveness by strengthening international cooperation, introducing advanced technology and management experience. The cooperation between Gax and Ellis has undoubtedly set a new benchmark for the internationalization of China's pharmaceutical industry.